Cargando…

Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation

SIMPLE SUMMARY: Radiofrequency ablation is a curative treatment for early-stage hepatocellular carcinoma (HCC), but many factors influence the survival of these patients and should be taken into consideration during treatment planning. Our retrospective study reports the outcome of radiofrequency ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Yuan-Hung, Huang, Tzu-Hsin, Yen, Yi-Hao, Lu, Sheng-Nan, Wang, Jing-Houng, Hung, Chao-Hung, Chen, Chien-Hung, Tsai, Ming-Chao, Kee, Kwong-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296493/
https://www.ncbi.nlm.nih.gov/pubmed/37370766
http://dx.doi.org/10.3390/cancers15123156
_version_ 1785063663315451904
author Kuo, Yuan-Hung
Huang, Tzu-Hsin
Yen, Yi-Hao
Lu, Sheng-Nan
Wang, Jing-Houng
Hung, Chao-Hung
Chen, Chien-Hung
Tsai, Ming-Chao
Kee, Kwong-Ming
author_facet Kuo, Yuan-Hung
Huang, Tzu-Hsin
Yen, Yi-Hao
Lu, Sheng-Nan
Wang, Jing-Houng
Hung, Chao-Hung
Chen, Chien-Hung
Tsai, Ming-Chao
Kee, Kwong-Ming
author_sort Kuo, Yuan-Hung
collection PubMed
description SIMPLE SUMMARY: Radiofrequency ablation is a curative treatment for early-stage hepatocellular carcinoma (HCC), but many factors influence the survival of these patients and should be taken into consideration during treatment planning. Our retrospective study reports the outcome of radiofrequency ablation (RFA) as primary treatment and analyzes seven factors related to a poorer prognosis: Age greater than 65 years, albumin-bilirubin (ALBI) grades 2 and 3, AST-to-platelet ratio index (APRI) greater than 1, tumor size larger than 3 cm, diabetes mellitus, end-stage renal disease, and tumor number greater than 1. By incorporating these variables, we developed a simplified nomogram that enables personalized predictions of overall survival following RFA for HCC. This tool can support physicians in clinical decision-making by providing individualized prognostic information. ABSTRACT: Our objective was to develop a predictive nomogram that could estimate the long-term survival of patients with very early/early-stage hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA). For this retrospective study, we enrolled 950 patients who initially received curative RFA for HCC at Barcelona Clinic Liver Cancer (BCLC) stages 0 and A between 2002 and 2016. Factors predicting poor survival after RFA were investigated through a Cox proportional hazard model. The nomogram was constructed using the investigated variables influencing overall survival (OS). After a median follow-up time of 6.25 years, 400 patients had died, and 17 patients had received liver transplantation. The 1-,3-,5-,7-, and 10-year OS rates were 94.5%, 73.5%, 57.9%, 45.7%, and 35.8%, respectively. Multivariate analysis showed that age greater than 65 years, albumin-bilirubin (ALBI) grades 2 and 3, AST-to-platelet ratio index (APRI) greater than 1, tumor size larger than 3 cm, diabetes mellitus, end-stage renal disease, and tumor number greater than 1 were significantly associated with poor OS. The nomogram was constructed using these seven variables. The validation results showed a good concordance index of 0.683. When comparing discriminative ability to tumor, node, and metastasis (TNM), BCLC, and Cancer of the Liver Italian Program (CLIP) staging systems, our nomogram had the highest C-index for predicting mortality. This nomogram provides useful information on prognosis post-RFA as a primary treatment and aids physicians in decision-making.
format Online
Article
Text
id pubmed-10296493
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102964932023-06-28 Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation Kuo, Yuan-Hung Huang, Tzu-Hsin Yen, Yi-Hao Lu, Sheng-Nan Wang, Jing-Houng Hung, Chao-Hung Chen, Chien-Hung Tsai, Ming-Chao Kee, Kwong-Ming Cancers (Basel) Article SIMPLE SUMMARY: Radiofrequency ablation is a curative treatment for early-stage hepatocellular carcinoma (HCC), but many factors influence the survival of these patients and should be taken into consideration during treatment planning. Our retrospective study reports the outcome of radiofrequency ablation (RFA) as primary treatment and analyzes seven factors related to a poorer prognosis: Age greater than 65 years, albumin-bilirubin (ALBI) grades 2 and 3, AST-to-platelet ratio index (APRI) greater than 1, tumor size larger than 3 cm, diabetes mellitus, end-stage renal disease, and tumor number greater than 1. By incorporating these variables, we developed a simplified nomogram that enables personalized predictions of overall survival following RFA for HCC. This tool can support physicians in clinical decision-making by providing individualized prognostic information. ABSTRACT: Our objective was to develop a predictive nomogram that could estimate the long-term survival of patients with very early/early-stage hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA). For this retrospective study, we enrolled 950 patients who initially received curative RFA for HCC at Barcelona Clinic Liver Cancer (BCLC) stages 0 and A between 2002 and 2016. Factors predicting poor survival after RFA were investigated through a Cox proportional hazard model. The nomogram was constructed using the investigated variables influencing overall survival (OS). After a median follow-up time of 6.25 years, 400 patients had died, and 17 patients had received liver transplantation. The 1-,3-,5-,7-, and 10-year OS rates were 94.5%, 73.5%, 57.9%, 45.7%, and 35.8%, respectively. Multivariate analysis showed that age greater than 65 years, albumin-bilirubin (ALBI) grades 2 and 3, AST-to-platelet ratio index (APRI) greater than 1, tumor size larger than 3 cm, diabetes mellitus, end-stage renal disease, and tumor number greater than 1 were significantly associated with poor OS. The nomogram was constructed using these seven variables. The validation results showed a good concordance index of 0.683. When comparing discriminative ability to tumor, node, and metastasis (TNM), BCLC, and Cancer of the Liver Italian Program (CLIP) staging systems, our nomogram had the highest C-index for predicting mortality. This nomogram provides useful information on prognosis post-RFA as a primary treatment and aids physicians in decision-making. MDPI 2023-06-12 /pmc/articles/PMC10296493/ /pubmed/37370766 http://dx.doi.org/10.3390/cancers15123156 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kuo, Yuan-Hung
Huang, Tzu-Hsin
Yen, Yi-Hao
Lu, Sheng-Nan
Wang, Jing-Houng
Hung, Chao-Hung
Chen, Chien-Hung
Tsai, Ming-Chao
Kee, Kwong-Ming
Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
title Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
title_full Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
title_fullStr Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
title_full_unstemmed Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
title_short Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
title_sort nomogram to predict the long-term overall survival of early-stage hepatocellular carcinoma after radiofrequency ablation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296493/
https://www.ncbi.nlm.nih.gov/pubmed/37370766
http://dx.doi.org/10.3390/cancers15123156
work_keys_str_mv AT kuoyuanhung nomogramtopredictthelongtermoverallsurvivalofearlystagehepatocellularcarcinomaafterradiofrequencyablation
AT huangtzuhsin nomogramtopredictthelongtermoverallsurvivalofearlystagehepatocellularcarcinomaafterradiofrequencyablation
AT yenyihao nomogramtopredictthelongtermoverallsurvivalofearlystagehepatocellularcarcinomaafterradiofrequencyablation
AT lushengnan nomogramtopredictthelongtermoverallsurvivalofearlystagehepatocellularcarcinomaafterradiofrequencyablation
AT wangjinghoung nomogramtopredictthelongtermoverallsurvivalofearlystagehepatocellularcarcinomaafterradiofrequencyablation
AT hungchaohung nomogramtopredictthelongtermoverallsurvivalofearlystagehepatocellularcarcinomaafterradiofrequencyablation
AT chenchienhung nomogramtopredictthelongtermoverallsurvivalofearlystagehepatocellularcarcinomaafterradiofrequencyablation
AT tsaimingchao nomogramtopredictthelongtermoverallsurvivalofearlystagehepatocellularcarcinomaafterradiofrequencyablation
AT keekwongming nomogramtopredictthelongtermoverallsurvivalofearlystagehepatocellularcarcinomaafterradiofrequencyablation